Clinical cancer research : an official journal of the American Association for Cancer Research
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer.
Filipa Lynce, Noah Graham, Bose S Kochupurakkal, Huy Nguyen, Brittany Bychkovsky, Philip D Poorvu, Victoria Attaya, Raechel Davis, Molly DiLullo, Alan D D'Andrea, Judy E Garber, Kavita Garg, Lee P Lim, Mark Li, Cloud P Paweletz
Published: 202510.1158/1078-0432.CCR-25-0571
Abstract
PURPOSE: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC), in patients with germline BRCA1/2 (gBRCA1/2)…
Preview only. Read the full abstract at the source